Lupin launches Favipiravir Drug Covihalt for treatment of mild to moderate COVID-19
5th Aug 2020

Lupin has launched its Favipiravir Drug in India under the brand name Covihalt for the treatment of mild to moderate COVID-19. Favipiravir has received authorization from the Drug Controller General of India (DCGI) for emergency use.

Lupin’s Covihalt dosage strength has been developed keeping in mind convenience of administration. It is available as 200 mg tablets in the form of a strip of 10 tablets, and priced at Rs. 49 per tablet.

Lupin is an innovation-led transnational pharmaceutical company headquartered in Mumbai, India.